(This November 8 story is repeated without any changes to the text) By Rishabh Jaiswal, Sabrina Valle and Maggie Fick NEW YORK/LONDON (Reuters) -U.S. drugmaker Pfizer has clinched a $10 billion deal ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity drug developer Metsera MTSR is finally over. Metsera, a New York-based ...

Pfizer Inc. is doubling down on the booming weight-loss drug race, with CEO Albert Bourla declaring the company will be a "formidable competitor" after securing a $10 billion deal to acquire ...

(Reuters) -Shares of Metsera fell over 15% in early trading on Monday, after the weight-loss drug developer accepted a sweetened offer from Pfizer to end a fierce bidding war between the pharma giant ...

NEW YORK (AP) — U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind ...

Matthew Herper covers medical innovation — both its promise and its perils. Mergers and acquisitions are a spectator sport. You couldn’t hope for a better match to watch than the competition between ...

Pfizer Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...